You are now leaving www.preprod-esmya-com.amarone.hu. Links to other websites are provided as a resource to our visitors.

Gedeon Richter accepts no responsibility for the content of other websites.

Esmya® – continues to transform the management of uterine fibroids

The first medical treatment for the long-term management* of uterine fibroids

Select a country
Healthcare professionals Close
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or register to view this area.


If you are a patient, you should visit fibroidsconnect.com, an online resource for patients outside the U.S.

Continue to the public portal Learn more about uterine fibroids, symptoms, treatment options, and find your nearest uterine fibroids expert.


If you are a member of the press, a blogger or an industry observer, please visit the Gedeon Richter or Preglem pressroom to get the latest press releases.

Continue to press room

About preprod-esmya-com.amarone.hu

Esmya.com is an international information resource intended for healthcare professionals with an interest in Esmya® (Ulipristal acetate 5mg) and in the management of symptomatic uterine fibroids.

This portal will give you a better understanding of the impact of uterine fibroids, also called leiomyoma or myoma; in addition, it will provide you with the information about the clinical development of Esmya® (Ulipristal acetate 5mg) and its mode of action.

As these pages are reserved for a healthcare professional audience, you will be asked to verify that you are a healthcare professional in order to visit some sections of the website.

Esmya® (Ulipristal acetate 5mg) is indicated for one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.1

Esmya® is also indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery.1

Uterine fibroids are the most common tumours in women of reproductive age, with a clinically relevant prevalence in 20-40% of women in this population2.
The condition has a significant impact on patient’s quality of life3, 4 and productivity4, 5 with heavy healthcare and work loss costs6.

1. Esmya® SmPC. May 2018.
2.Wallach EE, et al. Uterine Myomas: An overview of development, clinical features and management. Obstet 2. Gynecol 2004;104(2):393-406.
3. Spies JB., et al. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 2002; 99(2): 290-300.
4. Downes E., et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol 2010; 152(1): 96-102.
5. Lerner D., et al. Impaired work performance among women with symptomatic uterine fibroids. J Occup Environ Med 2008; 50: 1149-1157.
6. Hartmann KE., et al. Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol 2006; 108: 930-937.


For Healthcare Professionals only

This information contained in this website was specifically created for healthcare professionals. Please tick here to confirm that you are a licensed healthcare professional.
Registration conditions of ESMYA® could differ in each country, please refer to your local regulations for more information.

Accept Decline